251 related articles for article (PubMed ID: 19289490)
1. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.
Wang H; Zhang SY; Wang S; Lu J; Wu W; Weng L; Chen D; Zhang Y; Lu Z; Yang J; Chen Y; Zhang X; Chen X; Xi C; Lu D; Zhao S
Neuro Oncol; 2009 Dec; 11(6):790-802. PubMed ID: 19289490
[TBL] [Abstract][Full Text] [Related]
2. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.
Yang L; Shi T; Liu F; Ren C; Wang Z; Li Y; Tu X; Yang G; Cheng X
PLoS One; 2015; 10(3):e0120334. PubMed ID: 25781640
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots.
Skała E; Sitarek P; Toma M; Szemraj J; Radek M; Nieborowska-Skorska M; Skorski T; Wysokińska H; Śliwiński T
J Pharm Pharmacol; 2016 Nov; 68(11):1454-1464. PubMed ID: 27696406
[TBL] [Abstract][Full Text] [Related]
4. Migration-prone glioma cells show curcumin resistance associated with enhanced expression of miR-21 and invasion/anti-apoptosis-related proteins.
Yeh WL; Lin HY; Huang CY; Huang BR; Lin C; Lu DY; Wei KC
Oncotarget; 2015 Nov; 6(35):37770-81. PubMed ID: 26473373
[TBL] [Abstract][Full Text] [Related]
5. MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells.
Chen W; Yang Y; Chen B; Lu P; Zhan L; Yu Q; Cao K; Li Q
J Neurooncol; 2014 Oct; 120(1):43-53. PubMed ID: 25139024
[TBL] [Abstract][Full Text] [Related]
6. MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2.
Chen X; Zhang Y; Shi Y; Lian H; Tu H; Han S; Peng B; Liu W; He X
Int J Oncol; 2015 Oct; 47(4):1603-11. PubMed ID: 26323558
[TBL] [Abstract][Full Text] [Related]
7. Is mda-7/IL-24 a potential target and biomarker for enhancing drug sensitivity in human glioma U87 cell line?
Wang Q; Zhu Y; Yang P
Anat Rec (Hoboken); 2013 Aug; 296(8):1154-60. PubMed ID: 23794295
[TBL] [Abstract][Full Text] [Related]
8. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Pang J; Ye L; Zhao D; Zhao D; Chen Q
Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L.
Chen X; Zhu H; Ye W; Cui Y; Chen M
Mol Med Rep; 2019 Feb; 19(2):831-840. PubMed ID: 30535450
[TBL] [Abstract][Full Text] [Related]
10. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas.
Chen HY; Shao CJ; Chen FR; Kwan AL; Chen ZP
Int J Cancer; 2010 Apr; 126(8):1944-1954. PubMed ID: 19626585
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro.
Guo YF; Wang XB; Tian XY; Li Y; Li B; Huang Q; Zhang M; Li Z
World J Surg Oncol; 2012 Jun; 10():128. PubMed ID: 22741575
[TBL] [Abstract][Full Text] [Related]
13. Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells.
Sawada M; Nakashima S; Banno Y; Yamakawa H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Nozawa Y
Oncogene; 2000 Jul; 19(31):3508-20. PubMed ID: 10918609
[TBL] [Abstract][Full Text] [Related]
14. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
15. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy.
Feng X; Zhang B; Wang J; Xu X; Lin N; Liu H
Med Oncol; 2011 Mar; 28(1):24-30. PubMed ID: 20221717
[TBL] [Abstract][Full Text] [Related]
17. PDCD5 promotes cisplatin-induced apoptosis of glioma cells via activating mitochondrial apoptotic pathway.
Li H; Zhang X; Song X; Zhu F; Wang Q; Guo C; Liu C; Shi Y; Ma C; Wang X; Zhang L
Cancer Biol Ther; 2012 Jul; 13(9):822-30. PubMed ID: 22688731
[TBL] [Abstract][Full Text] [Related]
18. Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.
Germano IM; Emdad L; Qadeer ZA; Binello E; Uzzaman M
Cancer Gene Ther; 2010 Sep; 17(9):664-74. PubMed ID: 20523363
[TBL] [Abstract][Full Text] [Related]
19. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.
Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK
J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244
[TBL] [Abstract][Full Text] [Related]
20. Gli1 is a potential target for alleviating multidrug resistance of gliomas.
Cui D; Xu Q; Wang K; Che X
J Neurol Sci; 2010 Jan; 288(1-2):156-66. PubMed ID: 19818966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
